Harman Patil

Teduglutide

Updated on
Share on FacebookTweet on TwitterShare on LinkedIn
Trade names  Gattex, Revestive
Routes of administration  Subcutaneous injection
Legal status  US: ℞-only
Bioavailability  88%
AHFS/Drugs.com  gattex
ATC code  A16AX08 (WHO)
Molar mass  3,752.082 g/mol
ChemSpider ID  17296109
Teduglutide httpsuploadwikimediaorgwikipediacommonsthu
Pregnancy category  US: B (No risk in non-human studies)

Safety and efficacy of teduglutide after 52 weeks of treatment in patients


Teduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome. It works by promoting mucosal growth and possibly restoring gastric emptying and secretion. In Europe it has been granted orphan drug status and is marketed under the brand Revestive by Nycomed. It was approved by the United States under the name Gattex on 21 December 2012 and also is an orphan drug there.

Contents

Safety and efficacy of teduglutide after 52 weeks of treatment in patients


Medical uses

Up to a certain point, the gut can adapt to partial resections that result in short bowel syndrome. Still, parenteral substitution of water, minerals and vitamins (depending on which part of the gut has been removed) is often necessary. Teduglutide may reduce or shorten the necessity of such infusions by improving the intestinal mucosa and possibly by other mechanisms.

Adverse effects

Common adverse effects in clinical studies included abdominal discomfort (49% of patients), respiratory infections (28%), nausea (27%) and vomiting (14%), local reactions at the injection site (21%), and headache (17%).

Chemistry and mechanism of action

Teduglutide differs from natural GLP-2 by a single amino acid: an alanine is replaced with a glycine. This blocks breaking down of the molecule by dipeptidyl peptidase and increases its half-life from seven minutes (GLP-2) to about two hours, while retaining its biological actions. These include maintenance of the intestinal mucosa, increasing intestinal blood flow, reducing gastrointestinal motility and secretion of gastric acid.

References

Teduglutide Wikipedia


Similar Topics
Koodi Vazhnthal Kodi Nanmai
Robert L Byer
Andrew Neel
Topics